Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Chief Administrative Officer | October 28, 2022 | November 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date October 28, 2022 · Filed November 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,164 |
Reported balance
After 2022-10-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-10-28 · Sale · Disposed 448 · Balance 45,164 F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 1,510 shares of restricted stock units ("RSUs") on October 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2: Includes 28,389 shares underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 1,510 shares of restricted stock units ("RSUs") on October 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2: Includes 28,389 shares underlying RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2022 Filed Nov 1, 2022 22:03 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 448 | $21.54 | $9,649.92 |
DisclosureSEC source: 0001209191-22-055121 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,164 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 1,510 shares of restricted stock units ("RSUs") on October 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 28,389 shares underlying RSUs. Read SEC document |
| September 27, 2022 Filed Sep 29, 2022 21:14 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 259 | $22.73 | $5,887.07 |
DisclosureSEC source: 0001209191-22-051549 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,612 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 875 shares of restricted stock units ("RSUs") on September 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 29,899 shares underlying RSUs. Read SEC document |
| July 28, 2022 Filed Jul 29, 2022 20:57 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 452 | $21.27 | $9,614.04 |
DisclosureSEC source: 0001209191-22-043543 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,871 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 1,511 shares of restricted stock units ("RSUs") on July 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 30,774 shares underlying RSUs. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 22:03 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 265 | $20.31 | $5,382.15 |
DisclosureSEC source: 0001209191-22-039662 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,323 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 875 shares of restricted stock units ("RSUs") on June 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 32,285 shares underlying RSUs. Read SEC document |
| April 28, 2022 Filed May 3, 2022 00:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 435 | $25.57 | $11,122.95 |
DisclosureSEC source: 0001209191-22-026526 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,588 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 1,510 shares of restricted stock units ("RSUs") on April 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 33,160 shares underlying RSUs. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:49 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 294 | $29.87 | $8,781.78 |
DisclosureSEC source: 0001209191-22-021832 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,023 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 875 shares of restricted stock units ("RSUs") on March 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 34,670 shares underlying RSUs. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:28 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 48,340 | $0.00 Strike: $20.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005682 · doc4.xml · derivative · entry 2 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,340 Underlying: Common Stock · 48,340 shares Expires 2032-01-26 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:28 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 24,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005682 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,317 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. F2 · balance_after: Includes 35,545 shares underlying RSUs. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 00:50 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 260 | $33.10 | $8,606.00 |
DisclosureSEC source: 0001209191-21-071318 · doc4.xml · nonDerivative · entry 1 Porter Andy · CIK 0001899340 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,147 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 875 shares of restricted stock units ("RSUs") on December 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 11,375 shares underlying RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.